Clinical Trial Update: Study Evaluating PSI-697 in Patients With Scleritis [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PSI-697 for scleritis has been terminated. Wyeth, now a subsidiary of Pfizer, sponsored the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Scleritis

Drugs mentioned

• PSI-697

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Scleritis | Phase 1 | Status: TERMINATED